Join to access to all OVN content. Join for Free
The MSL Role - Big Pharma Vs. Small Biotech
MSL role differences large pharma vs small biotech career advice for MSLs MSL job market 2024 cultural differences in pharma

The MSL Role - Big Pharma Vs. Small Biotech


Share This Article


Summary

In this episode, Sarah Ussery joins to discuss her career journey and the distinctions between working in big pharma versus small biotech companies. Sarah provides an overview of both environments, highlighting the evolution of the MSL role and the responsibilities unique to each. She explores growth opportunities and the job market for both sectors, while addressing the challenges and cultural differences encountered in each setting. The conversation includes advice for MSLs navigating their careers in 2024, with insights on resume building and choosing between large pharma and small biotech. The episode concludes with closing remarks and a call to action.

My guest today is Sarah Ussery, Medical Affairs Leader who discusses the differences in MSL function between large pharma and small biotech.

  Sarah shares….

👉 What is considered Large Pharma VS Small Biotech
👉 How do MSL responsibilities differ by size of company
👉 How are MSLs evaluated differently by different companies
👉 How do the frustrations differ for MSLs in different size companies
👉 What are the cultural differences between different size companies

Click for Source
MSL role differences, large pharma vs small biotech, career advice for MSLs, MSL job market 2024, cultural differences in pharma

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN